This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Davison SL et al. (2005) Androgen levels in adult females: changes with age, menopause and oophorectomy. J Clin Endocrinol Metab 90: 3847–3853
Laumann EO et al. (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281: 537–544
Basson R et al. (2000) Report of the International Consensus Development Conference on Female Sexual Dysfunction: definitions and classifications. J Urol 163: 888–893
Somboonporn W et al. Benefits and risks of testosterone therapy in postmenopausal women taking estrogen alone or estrogen plus progestin. The Cochrane Database of Systematic Reviews, in press.
Goldstat R et al. (2003) Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 10: 390–398
Buster JE et al. (2005) Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105: 944–952
Davis SR et al. (2005) Circulating androgen levels and self-reported sexual function in women. JAMA 294: 91–96
Rossouw J et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333
Somboonporn W and Davis SR (2004) Testosterone and the breast: implications for testosterone therapy for women. Endocr Rev 25: 374–388
Wild S et al. (2000) Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 3: 101–105
Misso ML et al. (2005) Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. Menopause 12: 210–215
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author received unrestricted research grant support from Acrux Pty Ltd and Wyeth. She has acted as a Consultant or Advisory Board Member for Cellergy, AstraZeneca, Vivus, Acrus and Procter & Gamble, and has been an investigator for Procter & Gamble, Acrux and Organon.
Rights and permissions
About this article
Cite this article
Davis, S. The use of androgens for female sexual dysfunction. Nat Rev Urol 3, 176–177 (2006). https://doi.org/10.1038/ncpuro0439
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0439